Investlytic Investlytic
Log in Free Account
English
🕒 Last update: loading…01/11/2026

Stock Esperion Therapeutics, Inc. ESPR

Esperion Therapeutics, Inc. — Investlytic score 0/5 on the five criteria.

-
-
0/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 0/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ❌ Debt failed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: 29.63%

Price change 2019 → 2020: -56.40%

Price change 2020 → 2021: -80.77%

Price change 2021 → 2022: 24.60%

Price change 2022 → 2023: -52.01%

Price change 2023 → 2024: -26.42%

Price change 2024 → 2025: 68.18%

Price change 2025 → 2026: -14.05%

Price change 2026 (year to date): -14.29%

Financial growth

Revenue CAGR (8 years): 11.82%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Negative or zero equity.

P/E (Price/Earnings)

P/E ratio: -53.00

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 0.31% from the high over 6 months.

Insufficient correction (< 10.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

Create a free account Log in
02

Price trend

Price & trend

Interactive chart →
Loading chart…
03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

Create a free account Log in
04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

Create a free account Log in
05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

Create a free account Log in
06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

Create a free account Log in
+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 26/06/2013
ISIN code
US29664W1053
Workforce
304
full-time employees
Chief executive
Sheldon L. Koenig

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Esperion Therapeutics, Inc.

Is Esperion Therapeutics, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US29664W1053).

How many employees does Esperion Therapeutics, Inc. have?

304 full-time employees according to the latest published profile.

Who runs Esperion Therapeutics, Inc.?

Sheldon L. Koenig is the company's chief executive.